What are the treatment indications and applicable groups of Datopotamab?

Datopotomab Deruxtecan, referred to as Datopotamab) is an anti-TROP-2 antibody drug conjugate (ADC). To be approved for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has progressed after previously receiving EGFR targeted drugs and platinum-based chemotherapy. The drug targets the TROP-2 protein highly expressed on the surface of tumor cells and achieves precise killing by specifically binding and releasing cytotoxic drugs. This indication fills the treatment gap for refractory patients who have failed traditional treatments.

In addition toNSCLC, dabrotuzumab is also approved for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor Patients with advanced or metastatic breast cancer who are HER2-negative (HER2-), especially those who have previously received endocrine therapy and other standard therapies. When these patients are resistant to traditional therapies, Datopotamab provides a new treatment option by targeting TROP-2, showing good anti-tumor activity and tolerability.

CurrentlyDatopotamab is also being evaluated in multiple clinical trials for its efficacy against other tumors with highTROP-2 expression, such as head and neck cancer, gastric cancer, and triple-negative breast cancer (TNBC). Since TROP-2 is ubiquitously expressed in a variety of epithelial tumor cells, its indications are expected to be further expanded in the future. Ongoing multicenter, randomized controlled clinical trials will provide richer safety and efficacy data.

Datopotamabis suitable for adult patients aged ≥18 years old, who need to have certain organ functions, especially good liver and kidney functions, to ensure normal drug metabolism and excretion. In addition, patients must be TROP-2 positive tumors, confirmed by immunohistochemistry or molecular testing to ensure the effectiveness of targeted therapy. It is prohibited to be used by pregnant women, lactating women and patients with active infections. Strict monitoring is required before and after treatment to avoid serious adverse reactions.

In short, dabrotuzumab is an innovativeADCThe drug is currently approved for the treatment of advanced non-small cell lung cancer and HR+/HER2- advanced breast cancer. With the deepening of clinical research in the future, its scope of application is expected to be further expanded to benefit more cancer patients.

Reference materials:https://www.fda.gov/drugs/